Overview
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Status:
Completed
Completed
Trial end date:
2021-02-28
2021-02-28
Target enrollment:
0
0
Participant gender:
All
All
Summary
Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare: 1. the incidence, magnitude and duration of CMV and EBV viremia in the first year after transplant. 2. the side effects of the anti-viral drugs requiring dose reduction or cessation In addition, we will test renal tissue obtained from any biopsies post-transplant (surveillance or clinically indicated biopsies) by both polymerase chain reaction (PCR) and fluorescence in situ hybridization to assess for latent CMV and/or EBV.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science InstituteTreatments:
Acyclovir
Ganciclovir
Valacyclovir
Valganciclovir
Criteria
Inclusion Criteria:- All consenting kidney transplant recipients.
Exclusion Criteria:
- Non-consent.
- Recipients with allergies to valacyclovir or valganciclovir
- Recipients that are unable to independently understand the consent form and do not
have a legally authorized representative.